Gino Martel is experienced in corporate and commercial law, mergers and acquisitions, private equity financing, tax-driven reorganizations and the life sciences industry. He has been involved in the planning, structuring and implementation of numerous mergers and acquisitions, management buy-outs, corporate reorganizations, debt and equity financings, international tax structures, shareholder, partnership and joint venture arrangements and various other corporate and commercial transactions.
As particularly concerns the life sciences industry, Mr. Martel is Canadian corporate counsel to a number of multinational pharmaceutical companies and biotech companies and has been involved in many transactions involving pharmaceutical and biotech companies, including private and public financings, joint ventures, international tax structures, transfer pricing audits and assessments, buying and selling of pharmaceutical plants, companies, divisions and products, and in-licensing, out-licensing, ultra-generic licensing, distribution, co-promotion, manufacturing and pre-commercialization arrangements.
Selected client work
Mergers and Acquisitions
· Merger of Valeant Pharmaceuticals and Biovail Corporation
· Acquisition by Sanofi-aventis Canada Inc. of the skincare business of Canderm Pharma Inc.
· Acquisition by Valeant Canada Limited and Valeant Pharmaceuticals North America of (i) Laboratoire Dr Renaud and Renaud Skin Care Laboratories ($23 million) and (ii) VitalScience, DermaGlow and All Healthy Skin ($10.5 million)
· Sale by Baylis Medical Company Inc. of its worldwide pain management business to Kimberly-Clark Inc.
· Acquisition by Hydro-Québec Production of a 60% interest in the hydroelectric facility located on the Manicouagan River in Quebec from Abitibi-Consolidated Company of Canada, a subsidiary of AbitibiBowater Inc. ($615 million)
· Leveraged buy-out of the Cameo Crafts group of companies by Wind Point Partners
Life Sciences
· Acquisition by Celtic Therapeutics Holdings, L.P. and Kiacta Sàrl of the worldwide rights related to the Phase III investigational product candidate KiactaTM (eprodisate) from Bellus Health
· Three rounds ($26 million, $50 million and $45 million) of multi-tranche private equity financing of Enobia Pharma Corp.
· Two rounds of convertible debt/private equity financing of Zymeworks Inc. by CTI Life Sciences Fund
· Acquisition by Merck & Co., Inc. of the worldwide rights to Ambrilia Biopharma Inc.'s HIV/AIDS protease inhibitor program
Memberships and activities
· Canadian Tax Foundation
· Canadian Bar Association
Directorships
· Advisor to the board of directors of Enobia Pharma Corp.
· Secretary and board member of bioMérieux Canada, Inc.
· President and board member of Toba Pharma Inc.
· President and board member of Agnes Pharmaceutical Products Inc.
· Board member of The Kanawaki Golf Club
· Past board member of the Loyola Foundation
· Past President and board member of the Loyola Alumni Association
Related News
Les avocats de Sanofi en hausse, les droits à l'accès en baisse
Droit-inc.com highlights the firm's role in Sanofi-Aventis' acquisition of Canderm Pharma's assets, specifically contributions from partners Sara Joli-Coeur and Gino Martel.
22/06/2010
L'industrie réclame des mesures d'urgence
Gino Martel and Marie-Hélène Rochon talk to Les Affaires about the financial crisis' impact on the biotechnology sector.
21/03/2009